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Background/aim: To determine the prevalence of malignancy in thyroid incidentalomas (TIs) detected by fluorine-18 fluorodeoxyglucose
(18F-FDG) positron emission tomography/computed tomography (PET/CT).
Materials and methods: 18F-FDG PET/CT images were evaluated prospectively for the presence of thyroid uptake. The patients with a
TI were evaluated by an endocrinologist according to the predefined diagnostic algorithm. The final diagnosis was obtained clinically
and/or by pathology.
Results: TI was detected in 4.2% of 4204 patients. A malignant thyroid nodule was diagnosed in 29% and 33% of the focal and diffusefocal uptake groups, respectively. However, no malignancy was detected in the diffuse uptake group. The standardized maximum uptake
values (SUVmax) of the nodules were significantly higher in patients with thyroid malignancy than in patients with benign nodules
(P = 0.006). The calculated cut-off value of SUVmax for malignancy was 3.5. In 2 patients in whom the cytopathological diagnosis was
benign, malignancy was diagnosed after total thyroidectomy.
Conclusion: A malignant nodule was present in one-third of the patients with focal or diffuse-focal uptake. A SUVmax value of 3.5 was
considered as a cut-off value for the differentiation of a malignant lesion. Benign cytology in fine-needle aspiration biopsy for 2 patients
underestimated a thyroid malignancy.
Key words: 18F-FDG, PET scan, thyroid, cancer, second primary, prevalence

1. Introduction
A thyroid incidentaloma (TI) is the incidental detection
of lesion/lesions in the thyroid bed by a fluorine-18
fluorodeoxyglucose (18F-FDG) positron emission
tomography/computed tomography (PET/CT) scan that
has been performed for indications other than thyroid
scanning (1–3).
The 18F-FDG PET/CT scan is mostly used for oncologic
imaging (3–6). In physiologic conditions, 18F-FDG, which
demonstrates the glucose metabolism of the cells, is either
slightly or not accumulated by the thyroid gland. Rarely,
a TI may be observed by PET/CT scan. Its incidence has
been indicated to range between 1.2% and 4.3% in the
* These authors contributed equally to the study.
** Correspondence: ozhan.ozdogan@deu.edu.tr
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literature (2–4). Thyroid carcinoma was found in 14%
to 63.6% of patients with focal uptake, whereas diffuse
hyperthyroidism or thyroiditis was the final diagnosis in
patients with diffuse uptake (1–7). The malignancy rates
for focal and diffuse uptake in a systematic review were
34.8% and 4.4%, respectively (8).
The studies in the literature, excluding a few studies
performed on healthy volunteers, have retrospectively
investigated the prevalence of malignancy in 18F-FDG TI
patients. In the present study, we aimed to prospectively
investigate the incidence of TIs in patients with a known
primary tumor other than the thyroid carcinomas, and the
prevalence of malignancy in TI.
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2. Materials and methods
2.1. Study design and inclusion and exclusion criteria
The study was approved by the local ethics committee
of our institution in 2010. Oncologic 18F-FDG PET/CT
scans were prospectively evaluated for the presence of
any thyroidal 18F-FDG uptake until the end of 2012. The
patients were then referred to the endocrinology division
for clinical evaluation of thyroid function and morphology.
The inclusion criterion was the presence of any 18F-FDG
TI. The exclusion criteria were short life expectancy (<1
year) due to the primary cancer, the refusal to participate
by the patient at any time during the study, and failure to
reach a final clinical and/or cytological diagnosis.
2.2. 18F-FDG PET/CT imaging protocol
Blood glucose levels of the patients were under 200 mg/dL
following a minimum of 6 h of fasting. The 18F-FDG dose
was adapted according to the patient’s body weight. The
individual patient dose was 210 to 473 MBq. The PET was
obtained from the vertex to the midthigh using a Philips
Gemini TF (USA). The CT images were obtained with a
2-min bed time in 6 to 7 bed positions. The CT component
was used for attenuation correction. The CT scan settings
were 50–100 mAs and 120 kVp. A slice thickness of 5 mm,
a rotation time of 0.5 s, and a 512 × 512 matrix were used.
The 18F-FDG uptake in the thyroid was classified
as focal, diffuse, and diffuse-focal. The maximum
standardized uptake values (SUVmax) were recorded. The
18
F-FDG TI was mapped using the CT images according
to the side (right or left) and the location (upper, middle,
or lower lobe) of the nodule. The nodules on CT images
corresponding to the 18F-FDG uptake, as well as the
SUVmax of all focal lesions, were recorded. The patients
were then referred to the endocrinologist.
2.3. Clinical evaluation
The endocrinologist examined the patients clinically
and asked for the necessary laboratory tests including a
thyroid/neck ultrasonography (USG).
A fine-needle aspiration biopsy (FNAB) was
recommended for the nodules with 18F-FDG uptake
when the nodule was suitable for biopsy (at least 5–8
mm in size and not posteriorly located).
-

Patients with no thyroid nodules on USG or with
small nodules not suitable for biopsy were followed
clinically.

-

A FNAB was also recommended for the nodules
without 18F-FDG uptake but suspicious for
malignancy on USG.

-

A repeat FNAB was recommended if the result was
nondiagnostic or unsatisfactory.

-

A thyroidectomy was recommended if FNAB showed
malignancy or if there was suspicion of a malignancy.

-

Patients with benign cytology were followed clinically
and with USG at least once for in intervals of 9–12
months.

The final clinical decision was made either
histopathologically or clinically.
2.4. The USG protocol
The images were obtained with a Philips HDI 5000
ultrasound system (USA) in 2D mode and 7–12.5
MHz resolution. The sizes of both thyroid lobes and
the isthmus were measured. The echogenicity and the
vascularity of the gland were evaluated and reported. Size
and content (cystic, solid, or both) of the nodules, their
borders, their echogenicity, vascularity, and the presence
of halos and/or calcifications in the nodules were also
reported. The criteria of malignancy in the nodules were
hypoechogenicity, solidity, increased internal vascularity,
presence of microcalcifications in a nodule larger than 1
cm, and absence of a thin halo (9).
2.5. Fine needle aspiration biopsy and cytopathological
examination
Specimens were obtained by a 21-gauge needle. Air-dried
slides were stained with Giemsa stain, while those fixed in
96% alcohol were stained with hematoxylin and eosin. The
cytopathological evaluation was performed according to
the Bethesda Classification System of Thyroid Malignancy
Risk (10).
3. Results
Among 4204 18F-FDG PET/CT images obtained during
a period of 26 months, 18F-FDG TI was observed in 178
(4.2%). Sixty-two (34.8%) of the patients were excluded
from the study, either because of the short life expectancy
or because they refused to participate.
The mean age of the 116 patients included in the study
was 60.0 ± 12.6 years (ranging between 23 and 95 years).
Seventy-eight patients (67.2%) were female and 38 (32.8%)
male. The mean fasting blood glucose level was 110.6 ±
22.7 mg/dL (ranging between 74 and 195).
A focal/multifocal uptake was observed in 68 of the 116
patients (59.0%), while diffuse and diffuse-focal uptake
was observed in 35/116 (30.0%) and 13/116 patients
(11.0%), respectively.
3.1. The focal 18F-FDG-TI group
There were 86 focal areas in 68 patients with focal 18F-FDG
PET TI. A thyroid nodule was detected by USG in 82 of
the 86 uptake areas (95.3%). The mean size of the nodules
was 20.7 ± 13.1 mm (ranging between 5 and 81 mm).
The mean SUVmax value of these nodules was 5.9 ± 4.6
(ranging between 2.2 and 26.2). A FNAB was performed in
42 patients. A final cytopathological or clinical diagnosis
was obtained in 38 patients, whereas a final diagnosis
could not be obtained in 30, either because of the refusal of
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the first or subsequent FNAB by the patient or the refusal
of the surgery by the patient (Figure 1). The incidence of
malignancy was 28.9% (11/38). Figure 2 demonstrates
a patient with a focal 18F-FDG TI. The SUVmax of the
nodule on the right lobe was 21.2. Ultrasonographically,
there were no malignancy criteria in that nodule. The final
diagnosis following a total thyroidectomy was papillary
thyroid carcinoma.
3.2. The diffuse 18F-FDG TI group
There were 35 patients with diffuse 18F-FDG TI.
Ultrasonography revealed one or more nodules in 16 of
these patients, whereas there were no nodules in 19 patients.
The size of the nodules was 1 cm or greater in 9 patients
and smaller than 1 cm in 7 patients. Seventeen of these
cases (48.6%) were euthyroid, whereas hypothyroidism

and hyperthyroidism were detected in 14 patients (40.0%)
and in 4 patients (11.4%), respectively. Antithyroglobulin
and antithyroid peroxidase levels were high in 58.8%
and 76.5% of the patients, respectively. The final clinical
diagnosis was thyroiditis in 30 patients (Figure 1). There
was no malignancy in this group.
Figure 3 demonstrates a patient with a diffuse 18F-FDG
TI. The SUVmax of the thyroid gland was 6.6.
Ultrasonographically, there was no nodule. The final
diagnosis was autoimmune thyroiditis.
3.3. The diffuse-focal 18F-FDG TI group
Interestingly, in some patients with a homogeneous diffuse
uptake, there were one or more focal 18F-FDG uptake
areas that were more prominent than the background. We
defined this uptake pattern as diffuse-focal uptake. This

18F FDG PET-BT
TI patients
(n=116)
Surgery
malignant
(n=1)

Indeterminate
(n=1)

Refused FNAB
(n=1) **

Surgery
malignant
(n=2)

Benign
(n=21)

Surgery
benign
(n=3)

USG
no nodule
(n=1)

USG
no nodule
(n=3)

Surgery
benign
(n=1)

Benign
(n=23)

USG
suitable
for FNAB
(n=8)

Diffuse-focal
uptake
(n=13)

Focal
uptake
(n=68)

USG
suitable for
FNAB
(n=63)

FNAB
performed
(n=42)

Surgery
malignant
(n=3)

USG
milimetric
nodule
(n=4) †

USG
milimetric
nodule
(n=2) †

Refused
FNAB

Non
diagnostic
(n=3) ***

Malignant
(n=7)

Indeterminate
(n=2) ***

Malignancy
suspicion
(n=7)

(n=20) **
Surgery
malignant
(n=2)

Refused
surgery
(n=5) **

Diffuse uptake
(n=35)

No nodule
(n=18)

Lymphocytic
thyroiditis
(n=17)

No
pathology
(n=1)

USG
No or suspicious
nodule (n=19)

Suspicious
(n=1) *

USG nodule(s)
<1 cm (n=7)

Graves
disease
(n=1)

Lymphocytic
thyroiditis
(n=6)

USG
Nodules 1 cm
(n=9)
Refused
FNAB
(n=2) **

FNAB
performed
(n=7)
Lymphocytic
thyroiditis
(n=6)

Hashimato
thyroiditis
(n=1)

Figure 1. The flowchart demonstrating the diagnostic algorithm and the final diagnosis in patients with 18F-FDG TI.
Gray boxes: The patients for whom a final clinical diagnosis was reached. Black boxes: Excluded patients
*The USG was suspicious for the presence of a nodule.
**The patient refused a FNAB.
***The FNAB results were indeterminate or nondiagnostic and the patient refused any other tests.
†The nodules with TIs were small and/or posteriorly located such that a FNAB could not be performed in these patients.
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Figure 2. The CT, FDG PET, and fusion images of a patient with a focal 18F-FDG TI.

malignancy was diagnosed in 15 of the 50 patients (30.0%)
with focal and focal-diffuse 18F-FDG TI. Findings of
patients with proven thyroid malignancy are given in the
Table.
The SUVmax values of malignant nodules were
statistically different and higher in malignant nodules
than in benign ones (P = 0.006). The box plot graph of
these nodules is given in Figure 5. Upon evaluation of all
possible cut-off points, a SUVmax cut-off value of 3.5 was
found to be the best value with 73% sensitivity and 66%
specificity on ROC curve analysis, in differentiation of
malignancy from benign nodules.
The correlations between SUVmax values and the
nodule diameters were made using Spearman correlation
analysis. There were no correlations between SUVmax
values and the nodule diameters in either the benign and
malignant groups (P = 0.060 and 0.073, respectively).

Figure 3. The FDG PET maximum-intensity projection image of
a patient with diffuse 18F-FDG TI. The pathologic lymph nodes
in the left interpectoral and left axillar region in this patient
demonstrate the recurrence of the primary lymphoma.

pattern was present in 13 patients. A final cytopathological
or clinical diagnosis was obtained in 12 patients (Figure
1). A malignancy was diagnosed in four. The incidence
of malignancy in this group was 33.3% (4/12). Figure
4 demonstrates a patient with a diffuse-focal 18F-FDG
TI. There was a focal uptake in the left lobe-isthmus
localization (SUVmax: 6.4). A nodule was demonstrated
at that localization and did not demonstrate malignancy
criteria on USG. The patient refused a FNAB. The patient
was excluded from the study.
3.4. Statistical analysis
For statistical analyses, the focal 18F-FDG TI and focaldiffuse 18F-FDG TI groups were pooled together. Thyroid

4. Discussion
Nodules in the thyroid are not uncommon. The incidence
of finding a thyroid nodule on palpation is 2% to 7%
(11,12). However, the incidence increases to 14%–46%
using USG alone (2,3,13) and 16%–56% using CT or MRI
(2,14,15). On autopsy series, the incidence of finding at
least one nodule in the thyroid gland is reported to be 50%
(16).
In this prospective study, 18F-FDG TI was observed in
4.2% of 4204 oncology patients, which is consistent with
previous studies with rates reported to range between 1.1%
and 4.3% (1,7,17–23). The incidence of a TI demonstrated
by 18F-FDG PET/CT compared to other imaging
techniques is rare. This can be explained by the absence
of glucose transporter 1 (GLUT1) in the thyroid, which is
necessary for the uptake of glucose into the cell across the
plasma membranes. The thyroid gland also uses mostly the
free fatty acids in spite of glucose for energy metabolism
(24). Although a rare finding, 18F-FDG TI is important,
because the incidence of malignancy, mostly the primary
tumors of the thyroid rather than the metastatic ones, is
high in these patients (8).
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Figure 4. The CT, FDG PET, and fusion images of a patient with a diffuse-focal 18F-FDG TI.
Table. Characteristics of the patients with a final diagnosis of malignancy.
No.

Sex

Age

FDG PET

USG

Dx

SUVmax

Pathology

Tumor size (mm)

1

F

62

Focal

Suspicious

TT

3.0

FTC

24

2

F

44

Focal

Suspicious

TT

21.2

PTC

30

3

F

72

Focal

Suspicious

FNAB

2.9–6.3

PTC

19–25

4

F

83

Focal

Suspicious

FNAB

22.3

PTC

55

5

F

55

Focal

Benign

TT

4.8

PTC

5

6

F

81

Focal

Suspicious

TT

4.6

PTC

15

7

M

53

Focal

Suspicious

TT

7.9

PTC

12

8

M

82

Focal

Suspicious

FNAB

16.1

FTC

46

9

M

41

Focal

Benign

TT

10.8

PTC

12

10

M

56

Focal

Benign

TT

4.1

PTC

3–5

11

M

56

Focal

Suspicious

TT

6.3

PTC

*

12

F

65

Dif-foc

Malignant

FNAB

7.9

PTC

16

13

F

65

Dif-foc

Suspicious

TT

3.8–4.8

PTC

14

14

F

73

Dif-foc

Benign

TT

3.0

PTC

12

15

F

95

Dif-foc

Benign

FNAB

10.2

Undifferent. Ca.

12

Dx: Diagnosis, Dif-foc: diffuse and focal, TT: total thyroidectomy, FNAB: fine-needle aspiration biopsy.

Our study is the only prospective one investigating
F-FDG TIs in oncologic patients in the literature. The
calculated risk of malignancy in our study was 30%, which
was similar to two systematic reviews by Soelberg et al.
and Shie et al., in which the malignancy rates were 34.8%
and 33.2%, respectively (8,25). In contrast to our findings,
which are consistent with these systematic reviews, there
is great discrepancy in the literature about the prevalence
of malignancy in 18F-FDG TIs. In different studies, which
were all retrospective, the reported prevalence ranged
between 14.0% and 63.6% (17–22,26,27).
The discrepancy in the prevalence of malignancy may
be explained by the difference in ratios of patients with
18
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F-FDG TIs in whom a final diagnosis could be reached.
The risk of malignancy was 47% in one study where a final
diagnosis was obtained only in 15% of the patients with
18
F-FDG TIs (17). In contrast, the risk of malignancy was
15% in healthy volunteers who were imaged for screening.
In that study with healthy volunteers, the final diagnosis
was obtained (with FNAB and/or surgery) in 83% of the
patients (20).
The low risk of malignancy cannot be attributed to the
difference in the prevalence of the 18F-FDG TIs between
oncologic patient populations and healthy volunteers
because the prevalence was declared to be similar in these
groups (28). Nevertheless, the prevalence of malignancy
18
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25.00

SUVmax

20.00
15.00
10.00
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0.00
1.00
Malign

2.00
Benign

Figure 5. The box plot graph of SUVmax in malignant and
benign nodules.

of 18F-FDG TIs can be higher in patients with a known
primary tumor than the healthy volunteers owing to the
difference in age and sex of the patients. Thyroid cancer
incidence increases with increasing age, especially after the
third decade, and it is more frequent in females than males.
When compared with the study in healthy volunteers (28),
the mean patient age was higher in our group.
Geographic differences may also be considered as a
possible cause of the different risk ratios. However, in
one metaanalysis, there was no significant difference of
malignancy in 18F-FDG TI patients between different
geographic places (29). The pooled risk of malignancy was
36.2% in that metaanalysis, which was also very close to
the findings in our prospective study.
We think that the differences in the risk of malignancy
in 18F-FDG TIs are mostly due to the small percentage of the
patients with a final diagnosis obtained by the retrospective
studies. This seems to create a major patient selection bias.
This was also a major limitation of our prospective study.
In the presented study, 34.8% (62/178) of patients with an
18
F-FDG TI had to be excluded because they either did not
accept to participate in the study or their life expectancy
was short due to the primary malignancy. As a result, the
number of patients with an 18F-FDG TI included in the
study decreased significantly. Second, a final diagnosis
could not be obtained in 27.6% of the patients (32/116)
with 18F-FDG TIs due to the refusal of further tests by the
patients. Overall, we obtained a final diagnosis in only
47.2% (84/178) of patients with 18F-FDG TIs.
We had to exclude some of the patients with a FNAB
that was suspicious for malignancy because they either
refused further examination or thyroid surgery. The
malignancy rates in our study group could be higher if we
had obtained the final diagnosis for these patients. This
seems to be a major handicap while studying oncologic

patients. In a patient with the diagnosis of differentiated
thyroid carcinoma as a secondary malignancy, the
morbidity and mortality rates were almost always related
to the primary malignancy. A second thyroid malignancy,
which was mostly in the differentiated group, did not alter
the prognosis and the priority of the treatment strategy
in these patients. This may be accepted as an inborn
limitation for investigating the incidence of malignancy in
18
F-FDG PET incidentaloma patients.
The cut-off value of SUVmax for differentiating a
malignant from a benign nodule was reported to be 3.8–
6.0 in the literature (30–32). We found in this study that
a SUVmax cut-off value of 3.5 will distinguish between
malignant nodules with a sensitivity of 73% and benign
nodules with a specificity of 66%. These values for
sensitivity and specificity are consistent with the literature
values, ranging between 60% and 80% for sensitivity and
66.1% and 91.0% for specificity (30,33). In our study, the
mean SUVmax values of benign and malignant nodules
were 4.6 ± 2.2 (ranging between 2.5 and 13) and 8.8 ± 6.2
(ranging between 3.0 and 22.3), respectively. Although this
difference was statistically significant (P < 0.05), there was a
major overlap (Figure 5). This overlap was also apparent in
other studies. The declared SUVmax values for malignant
and benign lesions were in the ranges of 3.5–17.8 and 2.8–
32, respectively, in a study by Brindle et al. (34). There was
no significant correlation between SUVmax values and the
nodule diameters in our study excluding the dimensions
of the nodule as a cause for high 18F-FDG uptake. Instead,
the possibility of a poorly differentiated carcinoma is
potentially high in 18F-FDG TI patients (35). Considering
the overlap and the two malignant cases with a SUVmax
value of 3.0, we think that any focal uptake in a nodule
must be evaluated to rule out malignancy, regardless of the
SUVmax value.
Two patients with focal 18F-FDG TI decided to have
a total thyroidectomy, despite benign cytology on FNAB,
because the nodules fulfilled the malignancy criteria
also on USG. The final diagnosis was papillary thyroid
carcinoma in both patients. Tumors were located in
nodules with a high 18F-FDG uptake in both patients. A
benign cytology according to the Bethesda classification
system still has a 0%–3% risk for thyroid malignancy.
However, these values are valid for the general population
with a pretest probability of 5%–10%. In a study (36),
the risk of malignancy of 18F-FDG TIs was 11.3% with a
probably benign cytology on FNAB. In patients with a
higher pretest probability, the expected malignancy rate
with benign cytology will also be high. Therefore, a clinician
may evaluate benign cytology cautiously in patients with a
high pretest probability. We think that a benign diagnosis
by FNAB needs to be interpreted cautiously in patients
with risk factors for thyroid malignancy.
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In the diffuse 18F-FDG TI group, 31 of the 33 patients
with a final diagnosis (94%) had thyroiditis. Only one
patient (3%) had Graves’ disease. In the last patient (3%)
we could not demonstrate any pathology that would
explain the diffuse thyroidal uptake of 18F-FDG. Although
the thyroid gland commonly uses free fatty acids for energy
metabolism, some studies mentioned glucose (37). This
may be the explanation for this particular patient. There
was no thyroid carcinoma in the diffuse 18F-FDG TI group
in our study. Some studies reported a malignancy rate of
1.2%–6.4% in diffuse 18F-FDG PET/CT incidentaloma
groups (25,31). In the presented study we categorized
the diffuse/focal uptake group separately from the diffuse
uptake group and thyroid carcinomas were detected in the
diffuse/focal uptake group. This may be the reason for the

absence of any thyroid malignancy in the diffuse uptake
group in our study. We think that a thyroid malignancy
in a patient with diffuse 18F-FDG PET/CT incidentaloma
must be accepted as a false-negative finding if detected.
In conclusion, in this prospective study, we have found
that 18F-FDG TIs in an uptake pattern, focal or diffuse/focal,
were related to thyroid malignancy in about one-third of
the patients and were all primary thyroid malignancies,
mostly papillary carcinomas. The malignancy rate in this
prospective study is consistent with the systematic reviews.
The presence of any focal 18F-FDG uptake in a thyroid
nodule increases the pretest probability of malignancy in
that nodule regardless of the SUVmax value of that nodule,
and a benign FNAB result of that nodule must be evaluated
skeptically.
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